Nuveen’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $34.8M | Buy |
284,085
+156,171
| +122% | +$16.3M | 0.01% | 921 |
|
|
2026
Q1 | $13.5M | Buy |
127,914
+2,053
| +2% | +$182K | ﹤0.01% | 1383 |
|
|
2025
Q4 | $11M | Sell |
125,861
-2,523
| -2% | -$207K | ﹤0.01% | 1503 |
|
|
2025
Q3 | $8.53M | Sell |
128,384
-1,127
| -0.9% | -$64.1K | ﹤0.01% | 1639 |
|
|
2025
Q2 | $7.16M | Sell |
129,511
-23,260
| -15% | -$1.12M | ﹤0.01% | 1705 |
|
|
2025
Q1 | $7.39M | Buy |
152,771
+1,574
| +1% | +$66K | ﹤0.01% | 1722 |
|
|
2024
Q4 | $5.84M | Sell |
151,197
-80,877
| -35% | -$3.53M | ﹤0.01% | 1908 |
|
|
2024
Q3 | $10.4M | Sell |
232,074
-141,918
| -38% | -$5.73M | ﹤0.01% | 1574 |
|
|
2024
Q2 | $13M | Sell |
373,992
-304,209
| -45% | -$8.91M | ﹤0.01% | 1418 |
|
|
2024
Q1 | $19.6M | Buy |
678,201
+372,782
| +122% | +$10.1M | 0.01% | 1194 |
|
|
2023
Q4 | $7M | Sell |
305,419
-230,605
| -43% | -$4.03M | ﹤0.01% | 1789 |
|
|
2023
Q3 | $8.94M | Sell |
536,024
-399,937
| -43% | -$7.76M | ﹤0.01% | 1544 |
|
|
2023
Q2 | $25.9M | Buy |
935,961
+107,490
| +13% | +$2.69M | 0.01% | 914 |
|
|
2023
Q1 | $19.1M | Buy |
828,471
+467,757
| +130% | +$7.86M | 0.01% | 1080 |
|
|
2022
Q4 | $3.94M | Buy |
360,714
+22,170
| +7% | +$187K | ﹤0.01% | 2052 |
|
|
2022
Q3 | $2.85M | Buy |
338,544
+572
| +0.2% | +$5.41K | ﹤0.01% | 2201 |
|
|
2022
Q2 | $2.67M | Buy |
337,972
+33,860
| +11% | +$409K | ﹤0.01% | 2290 |
|
|
2022
Q1 | $2.35M | Buy |
304,112
+64,183
| +27% | +$1.81M | ﹤0.01% | 2427 |
|
|
2021
Q4 | $1.85M | Buy |
239,929
+76,843
| +47% | +$2.43M | ﹤0.01% | 2599 |
|
|
2021
Q3 | $1.26M | Sell |
163,086
-3,239
| -2% | -$138K | ﹤0.01% | 2894 |
|
|
2021
Q2 | $1.29M | Buy |
166,325
+21,625
| +15% | +$714K | ﹤0.01% | 2911 |
|
|
2021
Q1 | $1.12M | Buy |
144,700
+32,129
| +29% | +$813K | ﹤0.01% | 2853 |
|
|
2020
Q4 | $870K | Sell |
112,571
-726
| -0.6% | -$15.6K | ﹤0.01% | 2853 |
|
|
2020
Q3 | $876K | Buy |
113,297
+22,525
| +25% | +$423K | ﹤0.01% | 2740 |
|
|
2020
Q2 | $701K | Sell |
90,772
-8,301
| -8% | -$104K | ﹤0.01% | 2773 |
|
|
2020
Q1 | $700K | Sell |
99,073
-95,364
| -49% | -$715K | ﹤0.01% | 2656 |
|
|
2019
Q4 | $1.37M | Buy |
194,437
+43,906
| +29% | +$436K | ﹤0.01% | 2578 |
|
|
2019
Q3 | $1.81M | Buy |
150,531
+111,656
| +287% | +$1.41M | ﹤0.01% | 2446 |
|
|
2019
Q2 | $470K | Buy |
+38,875
| New | +$430K | ﹤0.01% | 3026 |
|
Other funds holding PTGX
FCM
RI
JJ
Nuveen's PTGX Position: Q2 2026 in Review
Nuveen increased its Protagonist Therapeutics (PTGX) stake by 122% in Q2 2026, buying an estimated $16.3M and bringing the position to 284,085 shares worth $34.8M. The position accounts for 0.01% of the portfolio, ranked #921.
Nuveen first reported a position in PTGX in Q2 2019 and has held it in 29 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.
- Nuveen held 284,085 shares of Protagonist Therapeutics worth $34.8M as of Q2 2026.
- Nuveen bought 156,171 Protagonist Therapeutics shares in Q2 2026, an estimated $16.3M.
- Protagonist Therapeutics made up 0.01% of Nuveen's portfolio in Q2 2026, its #921 holding.
- Nuveen first reported a position in Protagonist Therapeutics in Q2 2019 and has held it in 29 quarters since.
- 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.